🥇 First rule of investing? Know when to save! Up to 55% off InvestingPro before BLACK FRIDAYCLAIM SALE

Abbott shares rise after securing first win in premature infant formula trial

Published 11/01/2024, 07:16 AM
Updated 11/01/2024, 07:21 AM
© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox/File
ABT
-

(Reuters) - Abbott Laboratories (NYSE:ABT) shares rose nearly 5% before the bell on Friday, after a jury cleared the company and a Reckitt unit of liability in a lawsuit over their premature baby formulas' risks.

A jury in St. Louis, Missouri found on Thursday that Abbott and Reckitt unit Mead Johnson are not responsible for a young boy's severe intestinal disease, marking the first victory for the companies after large losses in two previous trials.

The lawsuit was one of about 1,000 similar cases pending nationwide over allegations the companies failed to warn that their specialized formulas used by newborn intensive care units in hospitals could cause necrotizing enterocolitis (NEC).

NEC almost exclusively affects premature infants and has an estimated mortality rate of more than 20%.

After the verdict and the "overwhelming societal support of infant formula, we think its prudent to lower the liability exposure and raise the odds of an Abbott victory in the trials, or at least improve the company's negotiating power in a settlement," J.P.Morgan analyst Robbie Marcus said in a note.

Marcus said investors were assuming a potential liability of $2 billion to $3 billion in NEC-related cases and the win could reduce Abbott's total liability by $500 million to $1 billion.

Verdicts in two lawsuits had already led to settlements of $60 million against Mead and $495 million against Abbott.

After that, however, U.S. regulatory agencies and some scientists convened by the National Institutes of Health said current evidence does not support the hypothesis that the formula causes NEC.

© Reuters. FILE PHOTO: The Abbott Laboratories facility where dozens of recalled types of powdered baby formulas were made leading to production being halted at the location in Sturgis, Michigan, U.S., May 20, 2022. Picture taken with a drone.  REUTERS/Eric Cox/File Photo

While the companies were not allowed to present the agencies' statement to the jury in the latest trial, Evercore analyst Vijay Kumar said it further strengthens Abbott's position in NEC-related lawsuits.

Abbott shares are priced at 24.25 times their estimated earnings for the next 12 months, a common benchmark for valuing stocks, compared with 14.73 for Reckitt.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.